J Neurosci. 2013 Agusta 7; 33 (32): 12982 – 12986.
doi: 10.1523/JNEUROSCI.5587-12.2013
PMCID: PMC3735881
Agnes Norbury,
1,2 Sanjay Manohar,1,2 Robert D. Rogers,3 da kuma Masud Husain1,2,4
Abstract
Neman jin daɗi na ɗabi'a, wanda aka bayyana a matsayin buƙatar jin daɗi daban-daban, masu rikitarwa, da kuma masu tsanani, yana wakiltar sha'awar jin daɗi da ba a bincika ba a cikin binciken ilimin halayyar ɗan adam. Yana da alaƙa da ƙaruwar haɗarin halaye daban-daban, gami da amfani da miyagun ƙwayoyi, caca, da kuma ayyukan jima'i masu haɗari. Bambance-bambancen mutum ɗaya a cikin neman jin daɗi da aka ruwaito yana da alaƙa da aikin dopamine na kwakwalwa, musamman a masu karɓar D2 masu kama da juna, amma har yanzu babu wata shaida da ke nuna rawar da dopamine ke takawa a cikin halayen neman jin daɗi a cikin mutane . A nan, mun bincika tasirin cabergoline mai zaɓin D2/D3 akan aiwatar da aikin zaɓi mai haɗari na yiwuwar a cikin mutane masu lafiya ta amfani da ƙira mai mahimmanci a cikin batun, wanda ke sarrafa placebo.
Cabergoline ya yi tasiri sosai kan yadda mahalarta suka haɗa sigina daban-daban game da yiwuwar da asara lokacin da suka zaɓi tsakanin zaɓuɓɓukan amsawa da ke da alaƙa da sakamako marasa tabbas. Mafi mahimmanci, waɗannan tasirin sun dogara sosai akan makin neman jin daɗi na asali. Gabaɗaya, cabergoline ya ƙara yawan jin daɗin zaɓi ga bayanai game da yuwuwar cin nasara; yayin da rage wariya bisa ga girman asarar da ke tattare da zaɓuɓɓuka daban-daban. An lura da mafi girman tasirin maganin a cikin mahalarta waɗanda ke da ƙarancin maki na neman jin daɗi. Waɗannan binciken sun ba da shaida cewa halayen ɗaukar haɗari a cikin mutane za a iya sarrafa su kai tsaye ta hanyar maganin dopaminergic, amma ingancin irin wannan magudi ya dogara da bambance-bambancen asali a cikin yanayin neman jin daɗi . Wannan yana jaddada mahimmancin la'akari da bambance-bambancen mutum ɗaya lokacin da ake binciken magudi na yanke shawara mai haɗari, kuma yana iya zama da mahimmanci ga haɓaka magunguna don cututtuka da suka shafi ɗaukar haɗari mai yawa a cikin mutane, kamar caca ta hanyar ilimin cuta.
Gabatarwa
Akwai gibin ban sha'awa tsakanin labaran da suka shafi yanke shawara da kuma halayen ɗan adam na yau da kullun ( Kahneman da Tversky, 1984 ). Misali, me ke motsa mutane su yi tsalle-tsalle a sararin sama, su ci abinci mai yaji, ko su yi layi na tsawon sa'o'i don hawa keken hawa mai ɗaukar mintuna? Babban ra'ayi a cikin nazarin halaye shine wanzuwar wani hali da ke da alaƙa da sha'awar neman "jijiyoyi masu ƙarfi," da kuma jure yiwuwar sakamako mai ban tsoro (haɗari) don amfanin irin waɗannan abubuwan jin daɗi ( Zuckerman, 1974 ).
Goyon bayan ra'ayin wata siffa guda da ta shafi ƙarfafawa ga ƙarfin ƙwarewa a cikin hanyoyin ji na ji ya samo asali ne daga lura da bambancin shan sigari, barasa, da maganin kafeyin; amfani da miyagun ƙwayoyi; da halayen jima'i masu haɗari a cikin manya da matasa ( Carmody et al., 1985 ; Gillespie et al., 2012 ; King et al., 2012 ). Shaida don canji mai haɗuwa a cikin haƙurin haɗari ana bayar da ita ta hanyar alaƙa tsakanin babban rahoton neman jin daɗi (SS) da ƙaruwar yawan shan ƙwayoyi masu yuwuwar cutarwa, caca mai yawa, da sauran halaye marasa dacewa ( Coventry da Brown, 1993 ; Roberti, 2004 ; Ersche et al., 2010 ).
An danganta bambance-bambancen mutum ɗaya a cikin neman jin daɗi da aikin dopamine na kwakwalwa (DA), musamman a masu karɓar D2-like (D2/D3/D4). A cikin mutane, yanayin SS yana da alaƙa da bambancin kwayoyin halitta a wurin karɓar D2 da D4 ( Ratsma et al., 2001 ; Hamidovic et al., 2009 ; Derringer et al., 2010 ), da kuma "samuwar mai karɓar D2/3," kamar yadda aka kiyasta ta hanyar 11 C-raclopride PET ( Gjedde et al., 2010 ). A cikin beraye, an nuna cewa mai aiki mai ƙarfi yana amsawa ga lada mara sharaɗi yana da laushi ga duka maganin antipsychotic flupenthixol (mai adawa da mai karɓar D1-D5) da amphetamine ( Olsen da Winder, 2009 ; Shin et al., 2010 ). Duk da haka, a halin yanzu babu wata shaida ta dalili a cikin mutane game da rawar da DA ke takawa wajen daidaita hali a matsayin aikin halayen SS.
A cikin wannan binciken, mun yi amfani da cabergoline - magani wanda ke da alaƙa mafi girma da kuma takamaiman alaƙa ga masu karɓar D2 fiye da wakilai da aka yi amfani da su a cikin binciken da aka yi a baya ( Kvernmo et al., 2006 ) - don faɗaɗa sakamakon da ba a saba gani ba a baya kan yadda ake sarrafa halayen ɗaukar haɗari ta hanyar magungunan D2 ( Hamidovic et al., 2008 ; Riba et al., 2008 ). Abu mafi mahimmanci, mun kuma yi la'akari da yiwuwar bambancin tasirin magunguna tare da halayen SS da aka ruwaito kai tsaye.
Dangane da shaidar hoto mai aiki daga yawan marasa lafiya da ke shan maganin agonist na dopamine na yau da kullun ( Abler et al., 2009 ), mun annabta cewa cabergoline zai ƙara tasirin bayanai game da yuwuwar samun lada, yayin da kuma zai iya rage tasirin mummunan sakamako, yayin zaɓin haɗari ko rashin tabbas. Kodayake binciken da aka yi a baya ya ba da rahoton ƙarin martani ga magungunan ƙarfafawa na DAergic a cikin masu sa kai na high SS (HSS), an kuma ba da shawarar cewa masu neman jin daɗi na iya samun tsarin DA mai ƙarfi ( Gjedde et al., 2010 ; duba kuma Tattaunawa), wanda zai annabta babban martani ga takamaiman agonists a cikin mutanen da ke da ƙarancin SS (LSS). Mun gano cewa cabergoline ya yi tasiri sosai ga zaɓin hankali ga bayanai game da yuwuwar da yuwuwar asara, kuma, a mahimmanci, girman waɗannan tasirin ya dogara sosai akan bambance-bambancen asali a cikin rahoton SS da kansu.
Kaya da matakai
Masu shiga.
Mahalarta sun kasance maza masu lafiya na 20 (ma'anar shekaru, shekarun 26.7; SD, 5.67 shekaru). Sharuɗɗan kaɗaita sun ƙunshi kowane ciwo na yanzu, halin da ake ciki na tarihi ko rashin lafiya, da / ko amfani da magunguna na nishaɗi a kan fiye da ɗayan lokaci a cikin watanni 6 da suka gabata. Duk abubuwan da aka gabatar sun ba da sanarwar rubutacciyar sanarwa kuma kwamitin kwastomomin Kwalejin London ya amince da binciken.
Zane.
An gudanar da binciken ne bisa ga tsarin placebo mai makanta biyu a cikin ɗalibai. A zaman farko, an tantance mahalarta don gano abubuwan da ba su dace da shan ƙwayoyi ba, sun ba da izini mai kyau, kuma sun saba da yanayin yanke shawara mai haɗari. Mutanen da aka yi binciken sun kuma kammala matakan rahoton kai na Barratt Impulsivity Scale (BIS-11) da UPPS (gaggawa; (rashin) juriya; (rashin jin daɗi); neman jin daɗi) ( Patton et al., 1995 ; Whiteside da Lynam, 2001 ), ma'aunin ƙarfin ƙwaƙwalwar aiki (tsawon lambobi na gaba bisa ga Wechsler Adult Intelligence Scale-III; The Psychological Corporation, 1997), da kuma ma'aunin ƙarfin tunani wanda ba na magana ba (Raven's 12-item Advanced Progressive Matrices; Pearson Education, 2010). A zaman gwaji na biyu da na uku (na gwaji), mahalarta sun isa da safe kuma an ba su kwamfutar hannu mai ɗauke da 20 mg na domperidone (wani maganin hana ƙwannafi), bayan mintuna 20 sai aka ba su 1.5 mg na cabergoline ko placebo (kwayoyi da placebo ba a iya bambanta su ba). An zaɓi wannan allurar ta fi wadda aka bayar a wani bincike da ya gabata inda aka lura da tasirin da bai dace ba kan ɗabi'a (1.25 mg; Frank da O'Reilly, 2006 ), tare da ƙara abin rufe fuska na domperidone don rage tasirin da zai iya haifarwa a jiki.
Domin a ba da damar matakan maganin a cikin jini su kai ga matsakaicin yawan da ake buƙata, an fara gwajin sa'o'i 2 bayan shan kwamfutar hannu ta biyu ( Andreotti et al., 1995 ). A kowace zaman gwaji, mahalarta sun kammala ma'aunin gani na ma'aunin analog na yanayi, tasirinsa, illolinsa na jiki, da kuma sanin yadda ake sarrafa maganin/placebo. An daidaita tsarin shan magani/placebo a tsakanin mutane, tare da mafi ƙarancin lokacin wankewa na makonni 2 tsakanin zaman gwajin guda biyu.
Misalin yanke hukunci mai hadari.
An binciki yanke shawara mai haɗari ta amfani da aikin zaɓin yiwuwar da Rogers da abokan aikinsa suka bayyana a baya ( Rogers et al., 2003 ; Murphy et al., 2008 ). A taƙaice, a kowace gwaji, an buƙaci mutane su zaɓi tsakanin caca biyu da aka gabatar a lokaci guda. Kowace caca an nuna ta a gani ta hanyar histogram, wanda tsayinsa ya nuna yiwuwar cin nasara a adadin maki da aka bayar. An nuna girman ribar da za a iya samu a kore a sama da kowace histogram, tare da girman asarar da za a iya samu a ƙasa da ja.
A kowane gwaji, caca ɗaya koyaushe ya ƙunshi 50: 50 damar cin nasara ko rasa maki 10 (da "sarrafawa" caca, ƙimar 0). Madadin ("gwaji") caca ya bambanta a cikin (1) yiwuwar samun nasara (0.6 ko 0.4), (2) girman damar da za a samu (maki 30 ko 70), da (3) girman hasarar mai yiwu (maki 30 ko 70) .
Wadannan kayan caca sun ƙetare gaba ɗaya, suna samar da nau'ikan gwaji takwas. An ba da ra'ayin gani (nasara / rasa) bayan kowane zaɓi, kuma an gabatar da bita da runningan maki da yawa kafin gwaji na gaba.
Abubuwan da aka kammala sun kammala ɓoyayyyoyi guda huɗu na gwaji na 20, kuma an umurce su cewa mafi girman jimlar da suka gudanar don cimma nasara za a canza su zuwa pence kuma a biya su a ƙarshen aikin azaman tsabar kuɗi. Hakanan an yi rikodin sauƙin amsawa (amsawa).
Binciken bayanan data zabi.
An bincika bayanai azaman zaɓi na caca na "gwaji" azaman aiki na yuwuwar nasara, girman yiwuwar samu, da girman asara mai yiwuwa. Musamman, an shigar da bayanan zabin daidaitattun matakan ANOVA tare da abubuwan batutuwa na kwayoyi, yuwuwar samun nasara, girman gatan da aka zata, da girman asarar da ake tsammanin. Haɗe da umarnin magani an haɗa shi azaman matsayin tsakanin abubuwan da aka sa a cikin samfurin. Anyi irin wannan binciken don bayanan lokacin amsawar. Hakanan an tantance zaɓin cikin sharuɗɗan darajar da aka samu da kuma "haɗarin" zaɓuɓɓukan caca, tare da ƙarshen ma'anar a matsayin SD na yiwuwar kowane caca da aka zaba. Dukkanin binciken ƙididdigar sakamako masu sauƙi sun kasance ta hanyar kwatanta daidaituwa ta amfani da daidaitawar Bonferroni don kwatancen ɗimbin yawa. Bayanai daga batutuwa ɗaya sun lalata saboda haka an cire su daga binciken.
results
Zaɓin bayanan zaɓin da aka zana
Babu wani muhimmin tasiri na tsarin magani, ko hulɗa tsakanin abubuwan da ke haifar da tsari na magani da magani, da aka gano (duka p > 0.09). Don haɓaka iko, saboda haka an yi watsi da tsarin magani daga samfurin don nazarin da ke gaba. Gabaɗaya, mahalarta sun zaɓi caca ta "gwaji" sau da yawa lokacin da yuwuwar cin nasara ta yi yawa idan aka kwatanta da lokacin da yake ƙasa ( F (1,18) = 40.305, p < 0.001, η p 2 = 0.691). An ƙara girman wannan tsarin yanke shawara a ƙarƙashin cabergoline dangane da placebo (yiwuwar shan magani * na cin nasara; F (1,18) = 6.733, p = 0.018, η p 2 = 0.272).
Masu shiga gasar sun kuma zaɓi caca ta "gwaji" sau da yawa lokacin da ribar da ake tsammani ta yi yawa fiye da lokacin da ribar da ake tsammani ta yi ƙanƙanta ( F (1,18) = 50.522, p < 0.001, η p 2 = 0.736). Duk da haka, babu wata shaida mai ƙarfi da ke nuna cewa wannan tsarin zaɓin ya bambanta a ƙarƙashin cabergoline (girman magani* na yuwuwar riba, F (1,18) = 3.615, p = 0.074).
A ƙarshe, masu sa kai sun zaɓi caca ta "gwaji" sau da yawa ba tare da an yi tsammanin asarar ta yi yawa ba fiye da lokacin da asarar da ake tsammani ta kasance ƙarami ( F (1,18) = 56.486, p = 0.001, η p 2 = 0.758). Wannan tsarin yanke shawara ya ragu sosai a ƙarƙashin cabergoline (girman magunguna* na asarar da za a iya samu, F (1,18) = 6.773, p = 0.018, η p 2 = 0.273). Don taƙaitaccen bayani game da waɗannan tasirin duba Hoto na 1.
Babu wani tasiri na cabergoline akan jimlar adadin zaɓin caca na "gwaji" ( p = 0.480), kuma babu wani muhimmin hulɗa mai girma da ya shafi ma'aunin magani (duk p > 0.2).
Yin hulɗa tare da bambance-bambancen mutum
An gano cewa sakamakon UPPS SS yana hulɗa sosai da tasirin miyagun ƙwayoyi akan halayen zaɓi [magani*yiwuwar cin nasara (pwin)*SS score, F (1,17) = 6.331, p = 0.022, η p 2 = 0.271; asarar magunguna**SS score, F (1,17) = 11.501, p = 0.003, η p 2 = 0.404; ta hanyar kwatantawa, shekaru, ƙiyasin IQ, ƙarfin ƙwaƙwalwar aiki, da jimlar sha'awar kai da aka ruwaito duk p > 0.3].
Hakika, hulɗar miyagun ƙwayoyi da abubuwan pwin da girman asarar da ake tsammani ya bayyana galibi ta hanyar mutanen da ke da ƙananan maki na SS ( Hoto na 2 A ). Binciken tasirin mai sauƙi ya nuna cewa, lokacin da ake bayyana ƙungiyoyin LSS da HSS ta hanyar matsakaicin rabon maki na SS, LSSs sun zaɓi ƙarin caca "na gwaji" lokacin da pwin ya yi yawa ( F (1,17) = 5.996, p = 0.025) da ƙasa da haka lokacin da pwin ya yi ƙasa ( F (1,17) = 7.808, p = 0.012) akan magani idan aka kwatanta da placebo. A akasin haka, ƙungiyar HSS ba ta bambanta ba a zaɓin zaɓin pwin mai ƙasa ko babba tsakanin yanayin magani da placebo ( p > 0.2).
LSSs sun kuma nuna rashin muhimmanci wajen zaɓar ƙarancin caca lokacin da asarar da za a iya samu ta ƙanana ( F (1,17) = 4.262, p = 0.0546), da kuma ƙarin caca lokacin da asarar da za a iya samu ta yi yawa ( F (1,17) = 3.052, p = 0.090; Hoto na 2 A ), akan cabergoline idan aka kwatanta da placebo. Babu ɗayan waɗannan tasirin da suka kusanci mahimmanci a cikin ƙungiyar HSS ( p > 0.2). Ƙungiyoyin HSS da LSS ba su bambanta sosai ba dangane da duk wani makin ƙananan matakan sha'awa da kansu suka bayar, shekaru, tsawon lambobi, ko ƙididdigar IQ (duk p > 0.3).
Don ƙididdige waɗannan tasirin a matakin mutum ɗaya, an ƙididdige ma'auni biyu na girman tasirin magani akan zaɓi ga kowane mutum (bambanci a cikin girman tasirin canjin yuwuwar cin nasara, ko girman asarar da za a iya samu, akan zaɓin gwargwado na caca tsakanin yanayin magani da placebo). An gano cewa maki na SS shine babban mai hasashen waɗannan ma'auni guda biyu ( r 2 adj = 0.229, p = 0.022; r 2 adj = 0.336, p = 0.005; nazarin komawar layi), amma ba kimanta IQ ba, tsawon lambobi, ko wani sakamakon rashin hankali da aka ruwaito kai tsaye (duk p > 0.1). A duka halayen biyu, mahalarta da ke da ƙananan maki na neman jin daɗi sun fi tasiri a cikin halayensu ta hanyar cabergoline ( Hoto na 2 B ). Ma'aunin biyu da kansu ba su da alaƙa sosai ( p = 0.117).
Lokacin isarwa
Babu wani muhimmin tasiri na yiwuwar cin nasara, girman yuwuwar riba, ko girman asarar da za a iya samu akan lokutan tattaunawa na mahalarta (duk F < 1), kuma babu wani muhimmin tasiri na cabergoline akan lokacin amsawa ( p = 0.204). Babu wani muhimmin tasirin hulɗa na miyagun ƙwayoyi, halayen caca, da maki SS akan lokutan tattaunawa (duk p > 0.3).
Valueimar da ake tsammani da haɗari
Darajar da ake tsammani ta caca tana da alaƙa mai kyau da zaɓin daidaito a ƙarƙashin placebo da cabergoline ( r 2 adj = 0.890, p < 0.001; r 2 adj = 0.737, p = 0.004; ma'aunin komawa baya ba su da bambanci sosai, p = 0.924). Rashin haɗarin caca (SD) bai da alaƙa da zaɓin daidaito a ƙarƙashin yanayin magani ( p > 0.5). Babu wani tasiri mai mahimmanci na magani akan matsakaicin ƙimar da ake tsammani ( p = 0.582) ko matsakaicin haɗarin caca da aka zaɓa ( p = 0.376). Hakanan babu wata muhimmiyar hulɗa ta magani da maki SS akan waɗannan ma'auni ( p > 0.2).
Kowane bambance-bambance a kan ka'idodi
Lokacin da aka yi la'akari da bayanai daga zaman placebo kawai, babu wata muhimmiyar hulɗa tsakanin maki SS da tasirin kaddarorin caca (pwin, girman ribar da ake tsammani da asara) akan zaɓi (duk p > 0.1). Hakanan babu wata muhimmiyar alaƙa tsakanin kowace ma'auni na zaɓi ɗaya (watau, matsakaicin haɗarin caca da aka zaɓa, matsakaicin ƙimar da ake tsammanin caca da aka zaɓa, da jimlar maki da aka ci) da maki SS (duk p > 0.1). Duk da haka, akwai wata muhimmiyar alaƙa mara kyau tsakanin maki SS da matsakaicin lokacin tattaunawa akan placebo ( r = −0.479, p = 0.038; Hoto na 3 A ), wanda bai bayyana a ƙarƙashin cabergoline ba ( p > 0.5). Wani ma'auni mai maimaitawa na ANOVA na matsakaicin lokacin tattaunawa tare da ma'aunin tsakanin batutuwa na ƙungiyar SS ya nuna cewa ƙananan mahalarta SS sun nuna yanayin zuwa jinkirin amsawa akan zaman placebo kawai (hulɗar ƙungiyar miyagun ƙwayoyi*SS, F (1,17) = 4.404, p = 0.0511; Hoto na 3 B ).
Abubuwan sakamako
A matakin da ba a gyara ba, mahalarta sun fi natsuwa sosai ( p = 0.033) kuma suna jin barci ( p = 0.017), kuma sun ba da rahoton ɗan ƙaramin ciwon kai ( p = 0.020), akan cabergoline idan aka kwatanta da placebo. Duk da haka, canji akan kowane ɗayan waɗannan matakan bai da alaƙa da ɗayan ma'aunin tasirin magani, ko maki SS da aka ruwaito kai tsaye (duk p > 0.4), yana nuna cewa wannan bai ba da gudummawa ga manyan tasirin cabergoline ko ga bambance-bambancen mutum ɗaya a cikin tasirin cabergoline ba. Ba a sami wani muhimmin tasirin magani akan duk wani tasirin jiki mai yuwuwa ba ( p > 0.25), yanayi, ko sikelin tasiri ( p > 0.16; jimilla 26) kuma ba a gano cewa ilimin sarrafa magunguna/placebo ya bambanta sosai tsakanin zaman gwaji ba ( t 1,18 = 1.681, p = 0.110).
tattaunawa
A cikin wannan binciken, mun sami muhimman tasirin allurai guda ɗaya na cabergoline mai agonist na D2/D3 akan yanke shawara a ƙarƙashin yanayin rashin tabbas ko haɗari, wanda, mafi mahimmanci, ya dogara ne akan bambance-bambancen asali a cikin halayen SS da aka ruwaito kai tsaye . Gabaɗaya, tasirin cabergoline shine ƙara girman canjin halayen zaɓi daidai da sigina bayyanannu game da yuwuwar cin nasara, da kuma rage canjin zaɓin daidai da bayanai game da girman asarar da za a iya samu ( Hoto na 1 ). Mafi mahimmanci, girman tasirin maganin an daidaita shi sosai ta hanyar ma'aunin UPPS SS na farko ( Hoto na 2 ) - wanda ya haifar da babban rabo na bambanci a cikin girman tasirin cabergoline akan yanke shawara mai haɗari (kimanin 23-34%). A cikin duka halayen biyu, mutanen da suka ba da rahoton ƙananan matakan halayen SS sun nuna ƙarfi na cabergoline akan halayen zaɓin su.
Tarin shaidu daga nazarin ɗan adam da na dabbobi yana nuna bambancin da ke tsakanin watsawar jijiyoyi ta D2R da aka yi a cikin bambance-bambancen mutum ɗaya a cikin halayen SS ( Ratsma et al., 2001 ; Blanchard et al., 2009 ; Hamidovic et al., 2009 ; Gjedde et al., 2010 ). Duk da haka, yunƙurin da aka yi a baya na sarrafa zaɓin haɗari kai tsaye a cikin dabbobi da mutane ta amfani da magungunan D2ergic ya haifar da sakamako marasa daidaituwa ( Hamidovic et al., 2008 ; Riba et al., 2008 ; St. Onge da Floresco, 2009 ; Simon et al., 2011 ). Wannan na iya zama saboda bambance-bambancen da ke cikin ma'anar haɗari (misali, bambancin da ke cikin yuwuwar girman lada da damar sakamako mai kyau), ko kuma saboda tasirin da ya dogara da kashi a cikin aikin magani.
Kasancewar masu karɓar D2 na presynaptic da na postsynaptic yana nufin ƙara magani na iya samun tasirin da ya saba wa juna kan watsawar dopaminergic ( Usiello et al., 2000 ). Duk da cewa masu karɓar D2 na presynaptic suna daidaita martanin phasic DA ba daidai ba, masu karɓar D2R na postsynaptic suna daidaita siginar tonic DA da ke cikin wakilcin haɗari ( Grace, 1991 ; Fiorillo et al., 2003 ; Schmitz et al., 2003 ; Schultz, 2010 ). Wannan yana haifar da matsaloli wajen fassara tasirin magani, musamman a ƙananan allurai inda kawai masu karɓar autoreceptors masu hana haɗin kai mafi girma za a iya ƙarfafa su. Mun yi ƙoƙarin tabbatar da ƙarfafa D2Rs na postsynaptic ta amfani da cabergoline agonist mai haɗin kai mai girma ( Kvernmo et al., 2006 ), a mafi girma fiye da wani bincike da ya gabata inda aka lura da tasirin magunguna marasa daidaito ( Frank da O'Reilly, 2006 ). An yi amfani da abin rufe fuska na Domperidone don rage tasirin da zai iya hana makanta, kamar tashin zuciya, kuma mutane gabaɗaya ba su san game da magudanar magani/placebo ba. Haka kuma ba mu sami wata shaida ta ƙaruwar mummunan tasirin maganin ba, wanda a da ake ɗauka a matsayin alamar tasirin magungunan presynaptic galibi (misali, Hamidovic et al., 2008 ).
Bincikenmu game da babban tasirin cabergoline a cikin LSSs na iya zama abin mamaki idan aka yi la'akari da rahotannin da suka gabata cewa HSSs suna nuna karuwar martanin jiki da na tunani ga abubuwan ƙarfafa dopaminergic, kamar amphetamine ( Kelly et al., 2006 ; Stoops et al., 2007 ), kuma wannan ƙimar SS tana da alaƙa mai kyau da sakin DA da amphetamine ya haifar a cikin striatum ( Riccardi et al., 2006 ). Duk da haka, Gjedde da abokan aiki sun yi jayayya kwanan nan kan shaidar PET cewa LSSs suna da ƙarancin yawan masu karɓar D2/D3 da ƙananan matakan DA na ciki fiye da takwarorinsu na HSS, ta yadda "ribar" tsarin DA (reactivity to dopamine) a cikin striatum yana da alaƙa da maki SS ( Gjedde et al., 2010 ). Don haka mahalarta LSS na iya samun babban ribar DA. Saboda haka, ana sa ran masu agonist na D2 kai tsaye, kamar yadda aka yi amfani da su a cikin bincikenmu, za su yi tasiri mai girma a cikin waɗannan mutane.
Don tallafawa wannan hasashe, akwai wasu shaidu da ke nuna cewa LSSs na iya samun ƙananan matakan DA na ciki fiye da HSSs. LSSs suna nuna matakan platelet mafi girma na monoamine oxidase (mai karɓar DA; Zuckerman, 1985 ; Carrasco et al., 1999 ), kuma an danganta matsayin LSS da ƙarancin aiki na dopa decarboxylase (DDC; enzyme mai iyakance ƙimar don haɗakar DA) a cikin striatum; ta hanyar bambance-bambancen duka a cikin kwayar halittar DDC kanta ( Derringer et al., 2010 ) da kuma Taq1a polymorphism ( Ratsma et al., 2001 ; Laakso et al., 2005 ; Eisenberg et al., 2007 ). Duk da haka, a halin yanzu babu wata shaida don ƙaruwar "riba" (misali, ta hanyar rashin lafiyar mai karɓa) a cikin watsawar DA a cikin mutane LSS sakamakon wannan.
Bincikenmu yana da wasu iyakoki. Na farko, cabergoline ba shi da takamaiman takamaiman alaƙar D2R. Hakanan yana da ƙarancin aikin agonist a 5-HT 2A , 5-HT 2B , da masu karɓar D1 ( Kvernmo et al., 2006 ). Saboda haka ba zai yiwu a tabbatar da tsarin da ke ƙarƙashin tasirin halayensa ba. Na biyu, kodayake ba mu sami wata shaida da ke tallafawa tasirin bambance-bambancen mutum ɗaya ko ƙaruwar radadin D2 akan zaɓin "hadari" dangane da bambance-bambance a cikin sakamako mai yuwuwa ba, a matakai huɗu wannan kwatancen wataƙila ba shi da ƙarfi, don haka bai kamata a ɗauki wannan sakamakon a matsayin ƙarshe ba. Gwaje-gwajen da za a yi nan gaba ta amfani da ƙarin haɗarin caca na iya ƙara bincika wannan. Bugu da ƙari, idan aka ba da samfurinmu na batutuwa 20, binciken bazai sami ƙarfin da ya dace ba kuma sakamakonsa zai amfana daga kwafi na gaba.
Duk da muhimmancinsa a asibiti, a halin yanzu ba a yi cikakken bincike kan yadda ake sarrafa yanke shawara a ƙarƙashin haɗari ba a tsakanin mutane da dabbobi ( Winstanley, 2011 ). A cikin wannan binciken, mun bayar da shaidar farko game da bambance-bambancen da ke tsakanin halayen SS suna shafar yadda ake sarrafa magani a fannin magunguna yana canza halayen ɗaukar haɗari. Waɗannan binciken sun jaddada mahimmancin la'akari da bambance-bambancen mutum ɗaya, kamar SS, lokacin da ake bincika yanke shawara mai haɗari, kuma yana iya zama da mahimmanci ga haɓaka magungunan magunguna don cututtukan da suka shafi ɗaukar haɗari mai yawa, kamar caca ta hanyar ƙwayoyin cuta.
Bayanan kalmomi
Wellcome Trust da United Kingdom Medical Council Council sun tallafawa wannan aikin.
Masu marubuta sun bayyana ba abin da ya shafi kudade.
References
- Abler B, Hahlbrock R, Unrath A, Grön G, Kassubek J. Rashin haɗari don caca mai ban tsoro: aiwatar da sakamako na ƙwanƙwasa a ƙarƙashin agonists na kullum. Kwakwalwa 2009; 132: 2396 – 2402. doi: 10.1093 / kwakwalwa / awp170. [PubMed] [Cross Ref]
- Andreotti AC, Pianezzola E, Persiani S, Pacciarini MA, Strolin Benedetti M, Pontiroli AE. Pharmacokinetics, pharmacodynamics, da kuma haƙuri na cabergoline, ƙwayar prolactin-rage ƙwaƙwalwa, bayan gudanar da ƙara yawan allurai na baki (0.5, 1.0, da kuma 1.5 milligrams) a cikin masu sa kai na maza masu lafiya. J Clin Endocrinol Metab. 1995; 80: 841 – 845. doi: 10.1210 / jc.80.3.841. [PubMed] [Cross Ref]
- Blanchard MM, Mendelsohn D, Stamp JA. Tsarin HR / LR: ƙarin hujja azaman samfurin dabba na abin mamaki. Neurosci Biobehav Rev. 2009; 33: 1145 – 1154. doi: 10.1016 / j.neubiorev.2009.05.009. [PubMed] [Cross Ref]
- Carmody TP, Brischetto CS, Matarazzo JD, O'Donnell RP, Connor MU. Yin amfani da sigari, giya, da kofi a cikin lafiya, maza da mata mazaunan gari. Lafiya na Lafiya. 1985; 4: 323-335. Doi: 10.1037 / 0278-6133.4.4.323. [PubMed] [Cross Ref]
- Carrasco JL, Sáiz-Ruiz J, Díaz-Marsá M, César J, López-Ibor JJ. Activityarancin platelet monoamine oxidase na aiki a cikin abin mamaki na neman masu wasan kwando. CNS Spectr. 1999; 4: 21 – 24. [PubMed]
- Coventry KR, Brown RI. Sensation neman, caca da jaraba giya. Addua. 1993; 88: 541 – 554. doi: 10.1111 / j.1360-0443.1993.tb02061.x. [PubMed] [Cross Ref]
- Derringer J, Krueger RF, Dick DM, Saccone S, Grucza RA, Agrawal A, Lin P, Almasy L, Edenberg HJ, Foroud T, Nurnberger JI, Jr, Hesselbrock VM, Kramer JR, Kuperman S, Porjesz B, Schuckit MA, Bierut LJ, Bierut LJ. Tsinkaye abin mamaki da ake nema daga kwayoyin halittar dopamine. Tsarin tsarin 'yan takarar. Psychol Sci. 2010; 21: 1282 – 1290. doi: 10.1177 / 0956797610380699. [PMC free article] [PubMed] [Cross Ref]
- Eisenberg DT, Campbell B, Mackillop J, Lum JK, Wilson DS. Lokacin haihuwa da dopamine mai karɓar ƙwaƙwalwar ƙwaƙwalwa tare da sha'awa, sha'awar nema da halayen haihuwa. PLoS Daya. 2007; 2: e1216. doi: 10.1371 / journal.pone.0001216. [PMC free article] [PubMed] [Cross Ref]
- Ersche KD, Turton AJ, Pradhan S, Bullmore ET, Robbins TW. Magungunan kwayoyi sun cutuka cikin rayuwa: sha'awar gaba da azanci-neman halayen mutum. Biol Psychiatry. 2010; 68: 770 – 773. doi: 10.1016 / j.biopsych.2010.06.015. [PMC free article] [PubMed] [Cross Ref]
- Fiorillo CD, Tobler PN, Schultz W. Bayanan komputa na yiwuwar sakamako da rashin tabbas ta hanyar neurons na dopamine. Kimiyya. 2003; 299: 1898 – 1902. doi: 10.1126 / Science.1077349. [PubMed] [Cross Ref]
- Frank MJ, O'Reilly RC. Aididdigar ƙirar ƙira a cikin ƙwarewar ɗan adam: nazarin ilimin psychopharmacological tare da cabergoline da haloperidol. Behav Neurosci. 2006; 120: 497-517. Doi: 10.1037 / 0735-7044.120.3.497. [PubMed] [Cross Ref]
- Gillespie NA, Lubke GH, Gardner CO, Neale MC, Kendler KS. Abubuwa biyu na bazuwar haɓaka tasirin girma don gano haɗarin da ke tattare da haɗarin giya da cannabis, matsakaiciyar fara amfani da canje-canje a cikin amfani da miyagun ƙwayoyi a cikin samfurin manya, 'yan tagwaye Alan Ruwa na Dogaro. 2012; 123: 220 – 228. doi: 10.1016 / j.drugalcdep.2011.11.015. [PMC free article] [PubMed] [Cross Ref]
- Gjedde A, Kumakura Y, Cumming P, Linnet J, Møller A. Daidaitawar daidaituwa ta hanyar daidaita tsakanin dopamine a cikin mawuyacin hali da kuma neman sha'awa. Proc Natl Acad Sci US A. 2010; 107: 3870 – 3875. doi: 10.1073 / pnas.0912319107. [PMC free article] [PubMed] [Cross Ref]
- Grace AA. Phasic a kan tonic dopamine saki da kuma daidaitawa na dopamine tsarin mayar da martani: Magana ga etiology na schizophrenia. Neuroscience. 1991; 41: 1 – 24. doi: 10.1016 / 0306-4522 (91) 90196-U. [PubMed] [Cross Ref]
- Hamidovic A, Kang UJ, de Wit H. Sakamakon ƙarancin magungunan pramipexole zuwa matsakaici da ƙima a cikin masu sa kai na lafiya. J Clin Murrayya 2008; 28: 45 – 51. doi: 10.1097 / jcp.0b013e3181602fab. [PubMed] [Cross Ref]
- Hamidovic A, Dlugos A, Skol A, Palmer AA, de Wit H. Nazarin bambancin kwayoyin halitta a cikin mai karɓa na Dopamine D2 dangane da inhibition na halayyar dabi'a da sha'awar / neman ji: binciken bincike tare da d-amphetamine a cikin masu halartar lafiya. Expand Clin Psychopharmacol. 2009; 17: 374 – 383. doi: 10.1037 / a0017840. [PMC free article] [PubMed] [Cross Ref]
- Kahneman D, Tversky A. Zaɓuɓɓuka, dabi'u, da kuma firam ɗin. Am Psychol. 1984; 39: 341 – 350. doi: 10.1037 / 0003-066X.39.4.341. [Cross Ref]
- Kelly TH, Robbins G, Martin CA, Fillmore MT, Lane SD, Harrington NG, Rush CR. Bambancin daidaikun mutane a cikin yanayin cutarwar miyagun ƙwayoyi: d-amphetamine da halin neman abin mamaki. Psychopharmacology (Berl) 2006; 189: 17 – 25. doi: 10.1007 / s00213-006-0487-z. [PMC free article] [PubMed] [Cross Ref]
- King KM, Nguyen HV, Kosterman R, Bailey JA, Hawkins JD. Haɗin-halayen halayen haɗarin jima'i da amfani da abu a cikin balagaggu na tasowa: shaida ga ƙungiyoyin jihohi da ƙungiyoyin ma'amala. Addua. 2012; 107: 1288 – 1296. doi: 10.1111 / j.1360-0443.2012.03792.x. [PMC free article] [PubMed] [Cross Ref]
- Kvernmo T, Härtter S, Burger E. Dubawa ne game da karɓar karɓa-karɓa da kaddarorin magunguna na agonists na dopamine. Clin Kark 2006; 28: 1065 – 1078. doi: 10.1016 / j.clinthera.2006.08.004. [PubMed] [Cross Ref]
- Laakso A, Pohjalainen T, Bergman J, Kajander J, Haaparanta M, Solin O, Syvälahti E, Hietala J. A1 allele na ɗan adam D2 dopamine mai karɓar ƙwaƙwalwar mutum yana da alaƙa da haɓaka aiki na tasirin L-amino acid decarboxylase a cikin batutuwa masu lafiya. Pharmacogenet Genomics. 2005; 15: 387 – 391. doi: 10.1097 / 01213011-200506000-00003. [PubMed] [Cross Ref]
- Murphy SE, Longhitano C, Ayres RE, Cowen PJ, Harmer CJ, Rogers RD. Matsayi na serotonin a cikin zaɓi mara haɗari: sakamakon tryptophan kari akan "tasirin tunani" a cikin masu sa kai na manya masu lafiya. J Cogn Neurosci. 2008; 21: 1709 – 1719. [PubMed]
- Olsen CM, Winder DG. Ationarfafa jijiyin da ke aiki tare da wasu nau'ikan abubuwa masu kama da kayan maye ga masu neman magani a cikin ƙwayar C57. Neuropsychopharmacology. 2009; 34: 1685 – 1694. doi: 10.1038 / npp.2008.226. [PMC free article] [PubMed] [Cross Ref]
- Patton JH, Stanford MS, Barratt ES. Tsarin tsari na Siffar Barratt Impulsiveness. J Clin Psychol. 1995; 51: 768-774. Doi: 10.1002 / 1097-4679 (199511) 51: 6 <768 :: AID-JCLP2270510607> 3.0.CO% 3B2-1. [PubMed] [Cross Ref]
- Ratsma JE, van der Stelt O, Schoffelmeer AN, Westerveld Kuma A, Boudewijn Gunning W. P3 mai yuwuwar abubuwan da suka faru, dopamine D2 mai karɓar A1 allele, da kuma neman ji-jiji a cikin manya manya na giya. Al'adar fata. 2001; 25: 960 – 967. [PubMed]
- Riba J, Krämer UM, Heldmann M, Richter S, Münte TF. Dopamine agonist yana ƙara haɗarin ɗaukar haɗari amma yana ba da haske game da aikin kwakwalwa mai lada. PLoS Daya. 2008; 3: e2479. doi: 10.1371 / journal.pone.0002479. [PMC free article] [PubMed] [Cross Ref]
- Riccardi P, Zald D, Li R, Park S, Ansari MS, Dawant B, Anderson S, Woodward N, Schmidt D, Baldwin R, Kessler R. bambance-bambancen jima'i a cikin tashin hankali na amphetamine-wanda aka haifar da [18F] fallypride a cikin yankuna masu ban tsoro da rashin tausayi : nazarin PET. Am J mahaukacin tabin hankali. 2006; 163: 1639 – 1641. doi: 10.1176 / appi.ajp.163.9.1639. [PubMed] [Cross Ref]
- Roberti JW. Yin bita da halayya da ilmin halitta game da abin da ake so. J Res Pers. 2004; 38: 256 – 279. doi: 10.1016 / S0092-6566 (03) 00067-9. [Cross Ref]
- Rogers RD, Tunbridge EM, Bhagwagar Z, Drevets WC, Sahakian BJ, Carter CS. Rushewar Tryptophan ya canza shawarar yankewa masu hidimar lafiya kwarin gwiwa ta hanyar sauya ayyukan lada. Neuropsychopharmacology. 2003; 28: 153 – 162. doi: 10.1038 / sj.npp.1300001. [PubMed] [Cross Ref]
- Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D. Presynaptik ne na dopaminergic neurotransmission. J Neurochem. 2003; 87: 273 – 289. doi: 10.1046 / j.1471-4159.2003.02050.x. [PubMed] [Cross Ref]
- Schultz W. Dopamine sigina don darajar sakamako da haɗari: ainihin asali da kwanan nan. Behav Brain Funct. 2010; 6: 24. doi: 10.1186 / 1744-9081-6-24. [PMC free article] [PubMed] [Cross Ref]
- Shin R, Cao J, Webb SM, Ikemoto S. Tsarin Amphetamine a cikin harsashi na kwakwalwa yana taimakawa haɗin halayyar hali tare da alamomi na gani a cikin berayen. PLoS Daya. 2010; 5: e8741. Doi: 10.1371 / journal.pone.0008741. [PMC free article] [PubMed] [Cross Ref]
- Simon NW, Montgomery KS, Beas BS, Mitchell MR, LaSarge CL, Mendez IA, Bañuelos C, Vokes CM, Taylor AB, Haberman RP, Bizon JL, Setlow B. Dopaminergic modulation na yanke shawara mai haɗari. J Neurosci. 2011; 31: 17460 – 17470. doi: 10.1523 / JNEUROSCI.3772-11.2011. [PMC free article] [PubMed] [Cross Ref]
- St. Onge JR, Floresco SB. Dopaminergic daidaituwa na yanke shawara dangane da hadarin. Neuropsychopharmacology. 2009; 34: 681 – 697. doi: 10.1038 / npp.2008.121. [PubMed] [Cross Ref]
- Stoops WW, Lile JA, Robbins CG, Martin CA, Rush CR, Kelly TH. Reinforarfafawa, kimantawa, aiwatarwa, da tasirin jijiyoyin jini na d-amphetamine: tasirin halin neman yarda. Mai shan iska Behav. 2007; 32: 1177 – 1188. doi: 10.1016 / j.addbeh.2006.08.006. [PMC free article] [PubMed] [Cross Ref]
- Usiello A, Baik JH, Rougé-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E. Ayyukan ɓoye na abubuwan biyu na isoforms na dopamine D2 masu karɓa. Yanayi. 2000; 408: 199 – 203. doi: 10.1038 / 35041572. [PubMed] [Cross Ref]
- Spiteside SP, Lynam DR. Hanyar Gaskiya Haske guda biyar da rashin karfi: ta amfani da tsarin tsari na mutum don fahimtar sha'awa. Bambancin Ind Indivir. 2001; 30: 669 – 689. doi: 10.1016 / S0191-8869 (00) 00064-7. [Cross Ref]
- Winstanley CA. Amfanin nau'ikan bera na nuna rashin karfi a cikin bunkasa magunguna don maganin rikicewar rikicewar cuta. Br J Pharmacol. 2011; 164: 1301 – 1321. doi: 10.1111 / j.1476-5381.2011.01323.x. [PMC free article] [PubMed] [Cross Ref]
- Zuckerman M. Abun da ake so shine motsi. Cigaban Pro 1974; 7: 79 – 148. [PubMed]
- Zuckerman M. Sensation yana nema, bugun jini, da kuma tsirrai. Neuropsychobiology. 1985; 13: 121 – 128. doi: 10.1159 / 000118174. [PubMed] [Cross Ref]
